The government’s Most-Favored-Nation (MFN) prescription drug portal features 43 drugs from the first five manufacturers to reach pricing agreements with the Trump Administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. Significantly lower costs for Ozempic, Bevespi, Wegovy, and many others. More prescription drug savings to follow as negotiations continue with other drug manufacturers.